The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and β-cell function.
Chronic inflammation arising from adipose tissue macrophage (ATM) activation may be central in type 2 diabetes etiology. Our objective was to assess the longitudinal associations of soluble CD163 (sCD163), a novel biomarker of ATM activation, with insulin sensitivity, β-cell function, and dysglycemia in high-risk subjects. Adults at-risk for type 2 diabetes in PROMISE had three assessments over 6 years (n=408). sCD163 was measured using fasting serum. Insulin sensitivity was assessed by HOMA2-%S and the Matsuda index (ISI). β-cell function was determined by insulinogenic index (IGI) over HOMA-IR and ISSI-2. Incident dysglycemia was defined as the onset of impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes. Generalized estimating equations (GEE) evaluated longitudinal associations of sCD163 with insulin sensitivity, β-cell function, and incident dysglycemia adjusting for demographic and lifestyle covariates. Areas under receiver-operating-characteristic curve (AROC) tested whether sCD163 improved dysglycemia prediction in a clinical model. Longitudinal analyses showed significant inverse associations between sCD163 and insulin sensitivity (% difference per SD increase of sCD163 for HOMA2-%S (β=-7.01, 95% CI -12.26 to -1.44) and ISI (β=-7.60, 95% CI -11.09 to -3.97) and β-cell function (ISSI-2 (β=-4.67, 95 %CI -8.59 to -0.58) and IGI/HOMA-IR (β=-8.75, 95% CI -15.42 to -1.56)). Increased sCD163 was associated with greater risk for incident dysglycemia (OR=1.04, 95% CI, 1.02 to 1.06 p<0.001). sCD163 added to a model with clinical variables improved prediction of incident dysglycemia (AROC=0.6731 vs 0.638, p<0.05). sCD163 was longitudinally associated with core disorders that precede the onset of type 2 diabetes.